LAURA CASTILLO: Open Payments
NPI 1992464432 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,272 in 121 payments from 40 companies in 2025. Trend: 2023 $474 · 2024 $1,747 · 2025 $3,272
Food & beverage: $3,008Education: $264
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $307 |
| Merck Sharp & Dohme LLC | 12 | $258 |
| Janssen Biotech, Inc. | 11 | $220 |
| PFIZER INC. | 8 | $174 |
| Daiichi Sankyo Inc. | 7 | $166 |
| GlaxoSmithKline, LLC. | 7 | $161 |
| TAIHO ONCOLOGY, INC. | 3 | $156 |
| Eisai Inc. | 4 | $120 |
| Astellas Pharma US Inc | 3 | $116 |
| PharmaEssentia USA Corporation | 5 | $108 |
Products named: KEYTRUDA, VENCLEXTA, RYBREVANT, LONSURF, OJJAARA, Lenvima, BESREMI, VERZENIO.
Industry payments across TX — which companies pay providers there.
